CD109 Antibody

1. GRP78 binds to and acts in concert with a glycosylphosphatidylinositol-anchored protein, CD109, in blocking TGF-beta signaling by promoting the routing of the TGF-beta receptor to the caveolae, thereby disrupting its binding to and activation of Smad2. PMID: 29654145
2. CD109 knockdown upregulated IL-8 expression through activation of TGF-beta/Akt/NF-kappaB pathway in human umbilical vein endothelial cells PMID: 27121053
3. High expression of CD109 in brain tumor stem cells is involved in glioma progression. PMID: 28888050
4. The CD109 protein was up-regulated in hepatocellular carcinoma tissue compared with adjacent noncancerous tissue. CD109 shRNA knockdown delayed the G1-S phase transition, abrogated cell proliferation, and increased cell apoptosis. Furthermore, CD109 impaired TGF-beta/Smad signaling through control of p-smad2. PMID: 27074923
5. CD109 is a putative biomarker for identifying a high-risk group among DLBCL patients. PMID: 28032275
6. Expression levels of CD109 was reduced significantly in psoriasis. Lower expression of CD109 and TGF-beta RI was highly correlated with higher expression of Smad7 and Ki67, suggesting that CD109 may induce the pathogenesis of psoriasis through Smad7-mediated degradation of TGF-beta RI. PMID: 26838754
7. sCD109 can bind TGF-beta, inhibit TGF-beta binding to its receptors and decrease TGF-beta signalling and TGF-beta-induced cellular responses. PMID: 26621871
8. These findings indicate that CD109 is an exosomal protein and that the C-terminal region of CD109 is required for its presence in the exosome. PMID: 26707640
9. CD109 may be a potential pathology marker for gallbladder squamous cell/adenosquamous carcinomas. PMID: 26249215
10. CD109 is specifically expressed in endothelial cells of cutaneous cavernous haemangioma. PMID: 25388101
11. expression increased in cutaneous squamous cell carcinoma PMID: 25271095
12. The results suggest that circulating endothelial cells express CD109 and represent a rare population of circulating tumor endothelial cells, that play a potentially useful prognostic role in patients with glioblastoma. PMID: 25506915
13. CD109 overexpression was significantly associated with surgical stage, distant metastasis, and poor prognosis in myxofibrosarcoma. PMID: 26031650
14. Three glioblastoma cell lines, SK-MG-1, U251MG and MG178, were tested and CD109 overexpression attenuated TGF-beta1 signaling and enhanced EGF signaling in SK-MG-1, but not in U251MG or MG178. PMID: 25724945
15. CD109 is highly expressed in TNBC and is a potential biomarker for the initiation, progression, and differentiation of breast cancer tumors. PMID: 25149155
16. CD109 plays a critical role in non-small-cell lung cancer (NSCLC) progression, and is overexpressed in advanced NSCLC PMID: 24667143
17. High expression of CD109 antigen regulates the phenotype of cancer stem-like cells/cancer-initiating cells in a novel epithelioid sarcoma cell line ESX and is related to poor prognosis of soft tissue sarcoma. PMID: 24376795
18. Hematopoietic cell marker CD109 is expressed in hepatic progenitor cells. PMID: 24396288
19. expression of CD109 (human platelet antigen 15) mRNA is different in various human cell types PMID: 23509816
20. The upregulation of CD109 protein in SSc may represent an adaptation or consequence of aberrant TGF-beta signaling in systemic sclerosis PMID: 22694813
21. CD109 is an important regulator of SMAD7/Smurf2-mediated degradation of TGFBR1. PMID: 21898545
22. CD109 release from the cell surface in human keratinocytes regulates TGF-beta receptor expression, TGF-beta signalling and STAT3 activation. PMID: 21539622
23. CD109 regulates TGF-beta receptor endocytosis and degradation to inhibit TGF-beta signaling. PMID: 21295082
24. Report PRSS3/mesotrypsin upregulation in breast cancer cells and identify CD109 as the functional proteolytic target of mesotrypsin. PMID: 20035377
25. These findings suggest that CD109 is involved in bladder tumorigenesis and is a potential target for cancer immunotherapy. PMID: 20946523
26. Processing of CD109 into 180 kDa and 25 kDa proteins by furin, followed by complex formation with the type I TGF-beta receptor is required for the regulation of TGF-beta signaling in cancer cells and keratinocytes. PMID: 20101215
27. Cell surface antigen CD109 is a novel member of the alpha(2) macroglobulin/C3, C4, C5 family of thioester-containing proteins. cDNA sequence determination and protein structure analysis given. PMID: 11861284
28. A tyrosine703serine polymorphism of CD109 defines the Gov platelet alloantigens. PMID: 11861285
29. Findings suggest that CD109 may become a molecular target for the development of new therapeutics for squamous cell carcinoma of various tissue origins. PMID: 15826242
30. CD109 plays a unique role in the regulation of isoform-specific TGF-beta signaling in keratinocytes. PMID: 16754747
31. Findings indicate that CD109 is a useful marker for the diagnosis of invasive breast and prostate carcinomas. PMID: 17493171
32. the novel gene HEPT3 may function through its noncoding RNA and its overexpression may play a role in hepatocarcinogenesis [HEPT3] PMID: 17611685
33. CD109 expression may play a role in the development of lung squamous cell carcinoma. PMID: 17922683
34. Up-regulation of CD109 expression is associated with carcinogensis of the squamous epithelium of the oral cavity. PMID: 19016750
35. Found with a mutation in 7% of colon cancers studied. PMID: 16959974

Show More

Hide All

HGNC: 21685

OMIM: 608859

KEGG: hsa:135228

STRING: 9606.ENSP00000287097

UniGene: Hs.399891